Brandin Cooks is expected to play for the Dallas Cowboys on Thursday after missing the last seven games with a knee injury, Cowboys EVP Stephen Jones said on 105.3 The Fan . "We're optimistic that we'll continue to get guys back. I think Cooks will be a player for us (on Thanksgiving)," said Jones. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated ELAN and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated . Investors have until December 6, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Elanco Animal Health Incorporated securities. The case is pending in the U.S. District Court of Maryland and is captioned Barpar v. Elanco Animal Health Incorporated , et al. , No. 24-cv-02912. What is the Lawsuit About? The complaint alleges that Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites. With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety. As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain of its executives made materially false and/or misleading statements to investors related to the FDA's approval of its drugs. Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated . What Can You Do? If you invested in Elanco Animal Health Incorporated ELAN you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated Or contact: Ross Shikowitz ross@bfalaw.com 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit https://www.bfalaw.com . https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated Attorney advertising. Past results do not guarantee future outcomes. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

In context: Fujikura Ltd., founded by Zenpachi Fujikura in 1885, continues to thrive, fueled by the rapid growth of AI products and research initiatives. Originally focused on producing silk and cotton-insulated wires, the company has evolved to specialize in advanced cable systems for the modern tech industry. After barely weathering the pandemic in 2020, Fujikura is now enjoying a period of unprecedented growth in the Japanese stock market, driven by demand in AI and data center operations. The Tokyo-based company specializes in manufacturing electrical equipment, including power and telecommunication systems, optical fiber devices, and more. According to a recent Bloomberg report, Fujikura has become the best-performing stock on the Nikkei 225 Stock Average, with its share price surging over 400 percent in 2024. The company is also set to join the widely followed MSCI global stock market index. One of Fujikura's most in-demand products is its ultra-thin fiber optic cables, which boast some of the smallest diameters in the industry. These cables can be deployed in tight spaces without requiring additional tunneling, according to CFO Kazuhito Iijima. Notably, Apple is one of Fujikura's largest customers. Iijima noted that demand for data center products began surging significantly around 2022, leaving company executives puzzled at first. Now, it's clear that AI is the primary driver behind the booming business. Fujikura is projected to achieve ¥104 billion ($674 million) in operating income during the current fiscal year, marking a 17 percent year-over-year increase. A substantial 70 percent of Fujikura's revenue comes from outside Japan, with 38 percent originating from the United States. In 2020, the company faced its first loss in a decade, attributed to the Covid-19 pandemic and escalating trade tensions between the US and China. The return of the Trump administration could reignite these challenges, but Fujikura has been preparing for such scenarios. To mitigate risks, Iijima confirmed that the company has established a US-based production facility dedicated to manufacturing high-density optical fiber cables. The plant is designed to comply with the Build America Buy America Act , ensuring resilience "even if new issues arise that are disadvantageous to imported materials," Iijima stated. Looking ahead, Fujikura is preparing for emerging opportunities as global data center capacity is projected to grow by 33 percent annually through 2030, according to McKinsey & Company. The company is also exploring future markets, with nuclear fusion reactors – a potential clean energy breakthrough – seen as a promising avenue that will likely require extensive cabling solutions.US-Google face off as ad tech antitrust trial comes to closeLewis scores 21, Marist beats Binghamton 69-51

Utah Hockey Club walks to arena after bus gets stuck in Toronto trafficKavena Shipanga: Namibia’s political landscape: A triumph of stability over opposition discord

Bears interim coach Thomas Brown insists he's focused on task at hand and not what his future holdsBest fall and winter farmers' markets to shop in Vancouver

None